PHOTODYNAMIC THERAPY OF EPITHELIAL SKIN TUMORS USING DELTA-AMINOLEVULINIC-ACID AND DESFERRIOXAMINE

PHOTODYNAMIC THERAPY OF EPITHELIAL SKIN TUMORS USING DELTA-AMINOLEVULINIC-ACID AND DESFERRIOXAMINE
复制标题

DOI:
10.1111/j.1365-2133.1995.tb02630.x
复制
发表时间:
1995-08-01
影响因子:
10.3
通讯作者:
ORTEL, B
ORTEL, B
中科院分区:
医学1区
文献类型:
--
作者:
FIJAN, S;HONIGSMANN, H;ORTEL, B

文献摘要

被引文献

相似文献

光动力疗法 (PDT) 使用光敏药物(例如卟啉)和光来治疗癌症。在本临床研究中,我们采用局部应用卟啉前体 δ-氨基乙酰丙酸 (ALA) 与去铁胺 (df) 组合来诱导内源性卟啉合成。使用由带有红色滤光片的卤素灯和光纤装置组成的光源进行照射。辐照度范围为 50 至 300 mW/cm(2)。我们用这种 PDT 疗法治疗了 49 名患者。在 32 名患者中,我们总共治疗了 34 例浅表基底细胞癌 (BCC) 和 22 例结节性 BCC,在 9 名患者中治疗了 43 例日光性角化病,在 8 名患者中治疗了 10 例鲍文氏病病变。单次治疗后,30 例 (88.2%) 浅表性基底细胞癌、7 例 (31.8%) 结节性基底细胞癌、43 例日光性角化病中的 35 例 (81.4%) 和 3 例 (30%) 鲍文氏病病变显示完全缓解。治疗后观察期长达20个月。六个结节性基底细胞癌和四个浅表性基底细胞癌需要重复治疗。在治疗前和治疗后以不同的时间间隔进行活检。使用 ALA-df 诱导的卟啉对皮肤肿瘤进行局部 PDT 可有效治疗上皮皮肤肿瘤。
Photodynamic therapy (PDT) uses photosensitizing drugs, such as porphyrins, and light for cancer treatment. In the present clinical study we employed topical application of the porphyrin precursor delta-aminolaevulinic acid (ALA) in combination with desferrioxamine (df) for the induction of endogenous porphyrin synthesis. Irradiation was performed with a light source consisting of a halogen lamp with a red filter and a fibreoptic device. Irradiances ranged from 50 to 300 mW/cm(2). We treated 49 patients with this PDT regimen. In 32 patients we treated a total of 34 superficial basal cell carcinomas (BCCs) and 22 nodular BCCs, in nine patients 43 solar keratoses, and in eight patients 10 lesions of Bowen's disease. After a single treatment, 30 (88.2%) of the superficial and seven (31.8%) of the nodular BCCs, 35 of 43 (81.4%) solar keratoses, and three (30%) of the Bowen's disease lesions showed complete remission. The post-treatment observation period was up to 20 months. Repeat therapy was required in six nodular and four superficial BCCs. Biopsies were obtained before treatment, and at variable intervals after treatment. Topical PDT of skin tumours with ALA-df-induced porphyrins is effective in the management of epithelial skin tumours.